VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Analyst Earnings Estimates
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.574B 22.06% | 8.931B 17.91% | 9.869B 10.51% | 11.108B 12.55% | 12.023B 8.24% | 13.218B 9.94% | 14.254B 7.84% | 15.472B 8.54% | 17.113B 10.61% | 19.013B 11.10% | 20.443B 7.52% | 22.845B 11.75% | |
| EBITDA YoY % growth | 2.908B -1.96% | 4.469B 53.69% | 4.54B 1.60% | 1.274B -71.94% | 5.748B 351.18% | 6.571B 14.32% | 7.217B 9.83% | 7.795B 8.01% | 8.877B 13.88% | 9.648B 8.69% | 10.262B 6.36% | 10.904B 6.26% | |
| EBIT YoY % growth | 2.782B -2.60% | 4.32B 55.29% | 4.359B 0.90% | 656.66M -84.94% | 5.571B 748.38% | 6.302B 13.12% | 7.154B 13.52% | 7.973B 11.45% | 8.671B 8.75% | 9.793B 12.94% | 10.365B 5.84% | 11.433B 10.30% | |
| Operating Margin | 36.73% | 48.38% | 44.17% | 5.91% | 46.34% | 47.68% | 50.19% | 51.53% | 50.67% | 51.51% | 50.70% | 50.05% | |
| EPS YoY % growth | 13.02 26.16% | 14.89 14.36% | 15.22 2.22% | 0.58 -96.21% | 19.01 3,195.61% | 21.14 11.20% | 23.35 10.44% | 26.45 13.28% | 28.89 9.22% | 32.89 13.85% | 36.10 9.76% | 42.64 18.10% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 4.10 -2.28% | 4.48 -5.83% | 4.60 135.86% | 4.74 8.18% | 4.88 18.98% | 5.21 16.28% | 5.11 11.06% | 4.59 -3.13% | 4.65 -4.75% |
| Revenue Q2Q % growth | 2.842B 12.88% | 2.854B 6.07% | 2.9B 9.62% | 2.995B 8.05% | 3.181B 11.93% | 3.124B 9.46% | 3.143B 8.38% | 3.185B 6.34% | 3.341B 5.03% |
| EBITDA Q2Q % growth | 1.253B 5.51% | 1.395B 9.86% | 1.376B 32.07% | 1.341B 3.79% | 1.473B 17.56% | 1.59B 13.98% | 1.541B 11.99% | 1.512B 12.75% | 1.495B 1.49% |
| EBIT Q2Q % growth | 1.193B 18.55% | 1.277B 4.99% | 1.306B 39.77% | 1.367B 20.83% | 1.457B 22.13% | 1.544B 20.91% | 1.495B 14.47% | 1.466B 7.24% | 1.448B -0.62% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 4.38 7.35% | 4.22 | 0.16 | 3.69% |
| Q2 2024 Q2Q % growth | -12.83 -429.82% | 3.00 | -15.83 | -527.57% |
| Q1 2024 Q2Q % growth | 4.76 56.07% | 4.14 | 0.62 | 14.85% |
| Q4 2023 Q2Q % growth | 4.20 11.70% | 4.18 | 0.02 | 0.36% |
| Q3 2023 Q2Q % growth | 4.08 1.75% | 4.05 | 0.03 | 0.66% |
| Q2 2023 Q2Q % growth | 3.89 8.06% | 3.96 | -0.07 | -1.75% |
| Q1 2023 Q2Q % growth | 3.05 -13.35% | 3.06 | -0.01 | -0.21% |
| Q4 2022 Q2Q % growth | 3.76 11.57% | 3.58 | 0.18 | 4.95% |
| Q3 2022 Q2Q % growth | 4.01 12.64% | 3.72 | 0.29 | 7.89% |
| Q2 2022 Q2Q % growth | 3.60 15.76% | 3.55 | 0.05 | 1.44% |
| Q1 2022 Q2Q % growth | 3.52 18.12% | 3.56 | -0.04 | -1.18% |
| Q4 2021 Q2Q % growth | 3.37 34.26% | 3.37 | 0.00 | 0.13% |
| Q3 2021 Q2Q % growth | 3.56 34.85% | 3.14 | 0.42 | 13.27% |
| Q2 2021 Q2Q % growth | 3.11 19.16% | 2.56 | 0.55 | 21.59% |
| Q1 2021 Q2Q % growth | 2.98 16.41% | 2.74 | 0.24 | 8.66% |
| Q4 2020 Q2Q % growth | 2.51 47.65% | 2.64 | -0.13 | -5.00% |
| Q3 2020 Q2Q % growth | 2.64 114.63% | 2.39 | 0.25 | 10.49% |
| Q2 2020 Q2Q % growth | 2.61 107.14% | 2.12 | 0.49 | 23.38% |
| Q1 2020 Q2Q % growth | 2.56 124.56% | 1.88 | 0.68 | 36.03% |
| Q4 2019 Q2Q % growth | 1.70 | 1.23 | 0.47 | 38.03% |
| Q3 2019 Q2Q % growth | 1.23 | 1.17 | 0.06 | 4.95% |
| Q2 2019 Q2Q % growth | 1.26 | 1.09 | 0.17 | 15.76% |
| Q1 2019 Q2Q % growth | 1.14 | 0.99 | 0.15 | 14.85% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.772B 11.61% | 2.778B | -6.1M | -0.22% |
| Q2 2024 Q2Q % growth | 2.646B 6.11% | 2.715B | -69.4M | -2.56% |
| Q1 2024 Q2Q % growth | 2.691B 13.30% | 2.63B | 60.6M | 2.30% |
| Q4 2023 Q2Q % growth | 2.518B 9.34% | 2.564B | -46.3M | -1.81% |
| Q3 2023 Q2Q % growth | 2.484B 6.39% | 2.55B | -66.5M | -2.61% |
| Q2 2023 Q2Q % growth | 2.493B 13.52% | 2.468B | 25.2M | 1.02% |
| Q1 2023 Q2Q % growth | 2.375B 13.22% | 2.384B | -9.2M | -0.39% |
| Q4 2022 Q2Q % growth | 2.303B 11.10% | 2.347B | -44.3M | -1.89% |
| Q3 2022 Q2Q % growth | 2.334B 17.64% | 2.271B | 63.3M | 2.79% |
| Q2 2022 Q2Q % growth | 2.196B 22.46% | 2.175B | 21.2M | 0.97% |
| Q1 2022 Q2Q % growth | 2.098B 21.64% | 2.118B | -20.5M | -0.97% |
| Q4 2021 Q2Q % growth | 2.073B 27.33% | 2.043B | 29.6M | 1.45% |
| Q3 2021 Q2Q % growth | 1.984B 28.99% | 1.893B | 91.2M | 4.82% |
| Q2 2021 Q2Q % growth | 1.793B 17.64% | 1.752B | 41.4M | 2.36% |
| Q1 2021 Q2Q % growth | 1.724B 13.81% | 1.69B | 34.3M | 2.03% |
| Q4 2020 Q2Q % growth | 1.628B 15.18% | 1.616B | 11.8M | 0.73% |
| Q3 2020 Q2Q % growth | 1.538B 61.96% | 1.515B | 23.3M | 1.54% |
| Q2 2020 Q2Q % growth | 1.525B 61.96% | 1.413B | 111.5M | 7.89% |
| Q1 2020 Q2Q % growth | 1.515B 76.50% | 1.313B | 202.1M | 15.39% |
| Q4 2019 Q2Q % growth | 1.413B | 1.033B | 380.3M | 36.82% |
| Q3 2019 Q2Q % growth | 949.8M | 969.92M | -20.12M | -2.07% |
| Q2 2019 Q2Q % growth | 941.3M | 903.29M | 38.01M | 4.21% |
| Q1 2019 Q2Q % growth | 858.4M | 867.48M | -9.08M | -1.05% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -1.67% | -0.48% | -3.14% | 245.84% |
| Revenue | 0.04% | 1.86% | 0.01% | 1.31% |